What Is InMed Pharmaceuticals Inc. (INM) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on InMed Pharmaceuticals Inc. at $1.59. With an estimated intrinsic value of $3.02 and 8 of 11 models pointing higher, the average implied return is +89.8%. The most optimistic model, EROIC, places fair value at $5.03 (+216.6%), while ML-RIV — the most conservative — estimates $0.25 (-84.1%). This +300.7% gap reflects genuine analytical uncertainty about InMed Pharmaceuticals Inc.'s intrinsic worth.
What Do the Models Say About INM?
11 of 13 models are currently active for INM. Of these, 8 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates INM's intrinsic value at $1.17, implying -26.4% downside from the current price. See which stocks rank higher →
How Does INM Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, INM ranks #166 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For InMed Pharmaceuticals Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.
Is INM a Value Trap?
CirclFi's Value Trap algorithm assigns INM a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for InMed Pharmaceuticals Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, InMed Pharmaceuticals Inc. earns a quality score of 5.4/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +300.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every INM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across INM's 11 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad